Novartis took a gamble that they could take the market by storm by luring away a bunch of GSK, Merck and Sanofi vaccine reps and leveraging their relationships to convert the market. Not a bad strategy but it's had limited success....and now they are stuck paying all of their vaccine reps 10-20% more than GSK, Merck and Sanofi. So, they have premium salary expenses and, by this point in the Menveo launch, they've already garnered all the potential benefit out of any of the personal relationships individual reps may have had....so why not dump them for something cheaper? Isn't a large portion of the sales force on a PIP anyway? Some good all their experience has done.